Post-transplantation Cyclophosphamide for Haploidentical Transplant From Maternal or Collateral Donors

Summary

In "beijing model" for haploidentical transplant, the rate of acute graft-versus-host disease (GVHD) from maternal or collateral donors was significantly higher than that from other kins. To reduce the GVHD incidence from maternal or collateral donors, post-transplantation cyclophosphamide is planned to be added into the protocol in "beijing model".

Timeline

Start

2015-03

Primary completion

2016-08

Completion

2017-03

Publications

• Wang Y, Wu DP, Liu QF, Xu LP, Liu KY, Zhang XH, Yu WJ, Xu Y, Huang F, Huang XJ. Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients. J Hematol Oncol. 2019 Sep 3;12(1):88. doi: 10.1186/s13045-019-0781-y.

Drugs

Indications